To the Editor: Identification of eosinophil chemotactic factor in a bronchogenic carcinoma1 suggests that eosinophilia in patients with lung cancer who are receiving radiation therapy2 may serve as a biologic marker of tumor presence. Although the relation between eosinophilia and cancer has been appreciated for at least a quarter of a century,3 its potential use in bronchogenic carcinoma has not been evaluated. During a prospective evaluation of cellular immunity in patients treated for bronchogenic carcinoma, serial eosinophil counts were obtained that permit the following estimate of the potential of this biologic marker. Eosinophilia (greater than 5 per cent eosinophils and. No extract is available for articles shorter than 400 words.
ASJC Scopus subject areas